Adverum completes Phase 3 ARTEMIS screening early; topline data accelerated to Q1 2027

Adverum Biotechnologies, Inc.

Screening for pivotal Phase 3 ARTEMIS trial of Ixo-vec in wet AMD to complete by Sept 30, ahead of schedule.
Full enrollment of at least 284 patients now expected in Q4 2025 (previously Q1 2026).
Topline data readout accelerated to Q1 2027; trial compares single Ixo-vec to aflibercept every 8 weeks.
ARTEMIS is the first of two Phase 3 registrational trials for Ixo-vec in wet AMD.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.